



## Lauren Maeda

Clinical Associate Professor, Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr MC 6505

Stanford, CA null

Tel (650) 498-6000 Fax (650) 498-5030

### Bio

---

#### CLINICAL FOCUS

- Cancer > Hematology
- Cancer > Lymphoma
- Medical Oncology

#### ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology

#### PROFESSIONAL EDUCATION

- Medical Education: Stanford University School of Medicine (2006) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2012) CA
- Residency: Stanford University Internal Medicine Residency (2011) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2012)

#### LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

### Research & Scholarship

---

#### CLINICAL TRIALS

- A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients, Not Recruiting
- Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML), Not Recruiting
- Phase 1 AGS67E Monotherapy in Refractory or Relapsed Lymphoid Malignancies, Not Recruiting
- Phase 1B Open-label of Combinations of CC-122,CC-223,CC-292 &Rituximab in DLBCL &Follicular Lymphoma, Not Recruiting
- Phase 1b/2 IPI-145 +/- Rituximab or Obinutuzumab in Previously Untreated CD20+ Follicular Lymphoma, Not Recruiting
- Phase 2 of MK-3475 (Pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma (cHL), Not Recruiting

- Phase I Atezolizumab (MPDL3280A) IV - Single Agent in Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Phase I CAL-101 w/ Chemo & Anti-CD20 mAb in Relapsed or Refractory Indolent B-cell NHL, MCL or CLL, Not Recruiting
- Phase I Extension Study of Clinical Activity of GS-1101 in Hematologic Malignancies, Not Recruiting
- Phase I GDC-0853 in Relapsed /Refractory B-Cell NHL and Chronic Lymphocytic Leukemia, Not Recruiting
- Phase I Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma after Allogeneic HCT , Not Recruiting
- Phase I Inotuzumab Ozogamicin with CVP in Relapsed/Refractory CD22+ Acute Leukemia, Not Recruiting
- Phase I REGN1979 in CD20+ B-Cell Malignancies Previously Treated w/ CD20-Directed Antibody Therapy, Not Recruiting
- Phase I/II BTK Inhibitor Ibrutinib in Combo w/ MEDI4736 in Relapsed or Refractory Lymphomas, Not Recruiting
- Phase I/II CHOEP Chemo + Lenalidomide as Front Line Tx in Stage II/III & IV Peripheral T-Cell NHL, Not Recruiting
- Phase I/II IMO-8400 in Relapsed or Refractory Waldenstrom's Macroglobulinemia, Not Recruiting
- Phase I/II Ipilimumab + Radiation in Melanoma, Non-Hodgkin Lymphoma and Colorectal Carcinoma, Not Recruiting
- Phase Ib Panobinostat +/-Idarubicin &Cytarabine Induction &High-Dose Cytarabine-Based Therapy in AML, Not Recruiting
- Phase Ib RO6870810 & Venetoclax +/- Rituximab, in Relapsed/Refractory DLBCL &/or Hi-Grade BCL w/ MYC, Not Recruiting
- Phase IB/II Vismodegib in Relapsed/Refractory AML and Relapsed/Refractory High Risk MDS, Not Recruiting
- Phase II ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin for High Risk Acute Promyelocytic Leukemia, Not Recruiting
- Phase II Hyper-CVAD + Dasatinib +/- Allogeneic Stem Cell Transplant in Ph Chromosome + and/or ALL , Not Recruiting
- Phase II Ibrutinib in Refractory Follicular Lymphoma, Not Recruiting
- Phase II Ibrutinib plus Rituximab in Previously Untreated Follicular Lymphoma, Not Recruiting
- Phase II Idarubicin & Ara-C +/- Pravastatin in Poor-Risk Acute Myelogenous Leukemia(AML) , Not Recruiting
- Phase II Idelalisib Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab &Alkylating Agents, Not Recruiting
- Phase II Lenolidomide +/- Azacitidine vs Azacitidine in Newly Diagnosed AML, Not Recruiting
- Phase II Nivolumab & Brentuximab Vedotin in Untreated HD Over age 60 or Unable to Receive ABVD Chemo, Not Recruiting
- Phase II Pracinostat plus Azacitidine in Elderly Patients with AML, Not Recruiting
- Phase II Sequential SGN-35, Adriamycin, Vinblastine, Dacarbazine (S-AVD) for Untreated HL, Not Recruiting
- Phase II Tipifarnib in Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Recruiting
- Phase III Axicabtagene Ciloleucef vs SoC Therapy in Relapsed/Refractory Diffuse Large BCell Lymphoma, Not Recruiting
- Phase III Azacitidine + BSC vs BSC as Maintenance Tx in AML in Complete Remission, Not Recruiting
- Phase III Bendamustine +Rituximab vs Ibrutinib +Rituximab vs Ibrutinib Alone in CLL, Not Recruiting
- Phase III Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage ALL, Not Recruiting
- Phase III Brentuximab Vedotin & CHP (A+CHP) vs CHOP in CD30-Positive Mature T-cell Lymphomas, Not Recruiting
- Phase III Ibrutinib or Placebo in Combo w/ Rituximab in Waldenström's Macroglobulinemia, Not Recruiting
- Phase III Ibrutinib plus R-CHOP in Newly Diagnosed Non-Germinal Center B-Cell Subtype DLBCL, Not Recruiting
- Phase III Ibrutinib, Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma, Not Recruiting
- Phase III Idelalisib (GS-1101) plus Rituximab in Previously Treated Indolent Non-Hodgkin Lymphomas, Not Recruiting
- Phase III Idelalisib(GS-1101) plus Bendamustine and Rituximab in Previously Treated Indolent NHLs, Not Recruiting
- Phase III Quizartinib vs Salvage Chemo in FLT3-ITD+ AML Refractory/Relapsed to First-Line Chemo, Not Recruiting
- Pilot Brentuximab Vedotin + AVD Chemotherapy in Newly Diagnosed Early Stage Risk Hodgkin Lymphoma, Not Recruiting
- Treatment Use Protocol for Ibrutinib (PCI-32765) in Relapsed or Refractory Mantle Cell Lymphoma, Not Recruiting
- Phase I/II JNJ-40346527, an FMS Inhibitor, in Relapsed or Refractory Hodgkin Lymphoma, Not Specified

## Publications

---

### PUBLICATIONS

- **Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)**  
Lee, D., Bharadwaj, S., Rana, M. S., Jensen, A., Wang, W., Ghalehsari, N., Sahaf, B., Mallampet, J., Elkordy, S., Latchford, T., Arai, S., Johnston, L., Hosoya, et al  
ELSEVIER.2024: 386-387
- **A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis.** *Blood advances*  
Shree, T., Haebe, S. E., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L., Alizadeh, A. A., Advani, R. H., Hoppe, R. T., Long, et al  
2023
- **Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma**  
Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L. S., Alizadeh, A. A., Advani, R. H., Hoppe, R., Long, et al  
AMER SOC HEMATOLOGY.2022: 6450-6451
- **CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.** *Blood cancer discovery*  
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., Beygi, S., Kanegai, A. M., Corbelli, K. S., Gabriel, E., Kurtz, D. M., Khodadoust, M. S., Gupta, et al  
2022
- **Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma**  
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., Advani, R., Maeda, L. S., Gupta, N. K., Khodadoust, M. S., Kurtz, D. M., Corbelli, K. S., Gabriel, et al  
AMER SOC HEMATOLOGY.2021
- **Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.** *Clinical lymphoma, myeloma & leukemia*  
Bennani, N. N., Tun, A. M., Carson, K. R., Geiger, J. L., Maeda, L. S., Savage, K. J., Rose, J., Pinter-Brown, L., Lunning, M. A., Abramson, J. S., Bartlett, N. L., Vose, J. M., Evens, et al  
2021
- **Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.** *Clinical lymphoma, myeloma & leukemia*  
Bennani, N. N., Tun, A. M., Carson, K. R., Geiger, J. L., Maeda, L. S., Savage, K. J., Rose, J., Pinter-Brown, L., Lunning, M. A., Abramson, J. S., Bartlett, N. L., Vose, J. M., Evens, et al  
2021
- **Stereotactic Radiotherapy for Recurrent Post- Transplant Primary Central Nervous System Lymphoma** *CUREUS*  
Benitez, C. M., Rahimy, E., Panjwani, N., Maeda, L. S., Soltys, S. G.  
2021; 13 (7)
- **Stereotactic Radiotherapy for Recurrent Post-Transplant Primary Central Nervous System Lymphoma.** *Cureus*  
Benitez, C. M., Rahimy, E., Panjwani, N., Maeda, L. S., Soltys, S. G.  
2021; 13 (7): e16537
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*  
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al  
2020; 217 (9)
- **Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply** *JOURNAL OF CLINICAL ONCOLOGY*  
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al

2019; 37 (9): 755-+

- **Reply to J. Wang et al.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al  
2019: JCO1801907
- **Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.** *Cureus*  
Albahr, A., Alhothali, W., Samghabadi, P., Maeda, L., Nagpal, S., Ajjan, A.  
2018; 10 (11): e3660
- **Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma**  
Jin, M. C., Schroers-Martin, J. G., Kurtz, D. M., Buedts, L., Esfahani, M. S., Macaulay, C., Sworder, B., Soo, J., Glover, C., Roschewski, M., Wilson, W. H., Duhrsen, U., Huettmann, et al  
AMER SOC HEMATOLOGY.2018
- **Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review** *CUREUS*  
Albahr, A., Alhothali, W., Samghabadi, P., Maeda, L., Nagpal, S., Ajjan, A.  
2018; 10 (11)
- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*  
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al  
2018; 36 (28): 2845-+
- **Circulating tumor DNA (ctDNA) in B-cell lymphoma**  
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Green, M. R., Liu, C. L., Zhou, L., Glover, et al  
WILEY.2018: 16-17
- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al  
2018: JCO2018785246
- **Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma** *58th Annual Meeting and Exposition of the American-Society-of-Hematology*  
Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., Lovejoy, A. F., Chabon, J. J., Liu, C. L., Zhou, L., Glover, C., Visser, B. C., Poultides, et al  
AMER SOC HEMATOLOGY.2016
- **Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma**  
Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., Chabon, J. J., Esfahani, M., Liu, C., Zhou, L., Glover, C., Visser, B. C., Poultides, et al  
AMER SOC HEMATOLOGY.2016
- **Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations**  
Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Glover, C., Advani, R. H., Maeda, L. S., Gupta, N. K., Levy, R., Kunder, et al  
AMER SOC HEMATOLOGY.2016
- **Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA** *SCIENCE TRANSLATIONAL MEDICINE*  
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., Zhou, L., Glover, C., Visser, et al  
2016; 8 (364)
- **Noninvasive molecular subtyping and risk stratification of DLBCL.**  
Scherer, F., Kurtz, D., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C., Zhou, L., Glover, C., Advani, et al

AMER SOC CLINICAL ONCOLOGY.2016

- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**  
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al  
AMER SOC HEMATOLOGY.2015
- **Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*  
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., Staudt, L. M., Jaffe, E. S., Wilson, et al  
2013; 368 (15): 1408-1416
- **A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma** *LEUKEMIA & LYMPHOMA*  
Warsch, S., Hosein, P. J., Maeda, L. S., Alizadeh, A. A., Lossos, I. S.  
2012; 53 (7): 1299-1305
- **Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*  
Nair, V. S., Maeda, L. S., Ioannidis, J. P.  
2012; 104 (7): 528-540
- **STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*  
Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., Horning, S. J.  
2011; 81 (5): 1374-1379
- **Current concepts and controversies in the management of early stage Hodgkin lymphoma** *LEUKEMIA & LYMPHOMA*  
Maeda, L. S., Lee, M., Advani, R. H.  
2011; 52 (6): 962-971
- **The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma** *CURRENT OPINION IN ONCOLOGY*  
Maeda, L. S., Advani, R. H.  
2009; 21 (5): 397-400
- **Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease** *9th International Conference on Malignant Lymphoma*  
Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., Rosenberg, S. A., Horning, S. J.  
AMER SOC CLINICAL ONCOLOGY.2007: 3902-7
- **Transcription arrest at an abasic site in the transcribed strand of template DNA** *CHEMICAL RESEARCH IN TOXICOLOGY*  
Tornaletti, S., Maeda, L. S., Hanawalt, P. C.  
2006; 19 (9): 1215-1220
- **Transcriptional inhibition by an oxidized abasic site in DNA** *CHEMICAL RESEARCH IN TOXICOLOGY*  
Wang, Y. L., Sheppard, T. L., Tornaletti, S., Maeda, L. S., Hanawalt, P. C.  
2006; 19 (2): 234-241
- **Effect of 8-oxoguanine on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II** *DNA REPAIR*  
Silvia, T. A., Maeda, L. S., Kolodner, R. D., Hanawalt, P. C.  
2004; 3 (5): 483-494
- **Effect of thymine glycol on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II** *JOURNAL OF BIOLOGICAL CHEMISTRY*  
Tornaletti, S., Maeda, L. S., Lloyd, D. R., Reines, D., Hanawalt, P. C.  
2001; 276 (48): 45367-45371